PARP Inhibitors in Ovarian Cancer

The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.